CVE-2019-1756

Cisco IOS XE Software Command Injection Vulnerability

Description

A vulnerability in Cisco IOS XE Software could allow an authenticated, remote attacker to execute commands on the underlying Linux shell of an affected device with root privileges. The vulnerability occurs because the affected software improperly sanitizes user-supplied input. An attacker who has valid administrator access to an affected device could exploit this vulnerability by supplying a username with a malicious payload in the web UI and subsequently making a request to a specific endpoint in the web UI. A successful exploit could allow the attacker to run arbitrary commands as the root user, allowing complete compromise of the system.

Category

7.2
CVSS
Severity: High
CVSS 3.0 •
CVSS 2.0 •
EPSS 0.66% Top 30%
Vendor Advisory cisco.com
Affected: Cisco Cisco IOS XE Software
Published at:
Updated at:

References

Frequently Asked Questions

What is the severity of CVE-2019-1756?
CVE-2019-1756 has been scored as a high severity vulnerability.
How to fix CVE-2019-1756?
To fix CVE-2019-1756, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2019-1756 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2019-1756 is being actively exploited. According to its EPSS score, there is a ~1% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2019-1756?
CVE-2019-1756 affects Cisco Cisco IOS XE Software.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.